Thus, we need new more systematic studies to acquire high quality and relatively reliable data of prognostic and clinicopathological significance of MYC to stratify breast cancer patients who would benefit from MYC targeted therapy and provide evidence to prospective treatment. This evidence concerns the gene MYC and breast carcinoma.